Wild-type and mutated IDH1/2 enzymes and therapy responses
Abstract Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism,
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …
epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the …
Metformin and cancer, an ambiguanidous relationship
The deregulation of energetic and cellular metabolism is a signature of cancer cells. Thus,
drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous …
drugs targeting cancer cell metabolism may have promising therapeutic potential. Previous …
Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles
Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor
prognosis and limited treatment options. Here, we describe the integrated analysis of …
prognosis and limited treatment options. Here, we describe the integrated analysis of …
Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion
Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity, reprogramming
metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG). Here, we found that 2-HG …
metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG). Here, we found that 2-HG …
Environment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metformin
Metformin use is associated with reduced cancer mortality, but how metformin impacts
cancer outcomes is controversial. Although metformin can act on cells autonomously to …
cancer outcomes is controversial. Although metformin can act on cells autonomously to …
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Mutations in IDH induce epigenetic and transcriptional reprogramming, differentiation bias,
and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell …
and susceptibility to mitochondrial inhibitors in cancer cells. Here, we first show that cell …
Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
S Tommasini-Ghelfi, K Murnan, FM Kouri… - Science …, 2019 - science.org
Isocitrate dehydrogenases (IDHs) are critical metabolic enzymes that catalyze the oxidative
decarboxylation of isocitrate to α-ketoglutarate (αKG), NAD (P) H, and CO2. IDHs …
decarboxylation of isocitrate to α-ketoglutarate (αKG), NAD (P) H, and CO2. IDHs …
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
IC Hvinden, T Cadoux-Hudson, CJ Schofield… - Cell Reports …, 2021 - cell.com
The most frequently mutated metabolic genes in human cancer are those encoding the
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …
enzymes isocitrate dehydrogenase 1 (IDH1) and IDH2; these mutations have so far been …
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to
IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the …
IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the …
Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics
EG Armitage, AD Southam - Metabolomics, 2016 - Springer
Introduction Cellular metabolism is altered during cancer initiation and progression, which
allows cancer cells to increase anabolic synthesis, avoid apoptosis and adapt to low nutrient …
allows cancer cells to increase anabolic synthesis, avoid apoptosis and adapt to low nutrient …